VirTus Respiratory Research is pleased to share positive topline results from Ethris’ Phase 2a clinical trial of ETH47, conducted by VirTus using its established human rhinovirus challenge model in patients with asthma. The study demonstrated promising antiviral activity, including a 40-fold reduction in viral load compared with placebo at the peak of viral replication, alongside encouraging improvements in respiratory symptoms and rescue medication use. These results represent an important milestone in the development of ETH47 and further demonstrate the value of human viral challenge studies in evaluating novel respiratory therapies and generating early clinical evidence to support further development.